2024-06-05T15:42:38-05:00 2023-12-31 300514455 Hoelting & Company Inc 31 East Platte Avenue Suite 300 Colorado Springs CO 80903 990 2023-01-01 203186261 Society for Translational Oncology SOCI 9196415323 PO Box 12412 Durham NC 27709 Kenneth Lee Treasurer 9196415323 2024-06-05 1 Kenneth Lee 999009999 1 Scott C Hoelting P00100024 7196301091 2024-06-05 0 AAL1 IAL1 2023 2023-04-26 12:10:37Z Kenneth Lee PO Box 12412 Durham NC 27709 1087444 0 X WWW.STO-ONLINE.ORG X 2000 NC As a nonprofit professional association dedicated to providing continuing education for oncology and hematology/oncology professionals, STO helps improve the quality, safety and equity of caring for cancer patients and others with weakened immune systems by ensuring the following expected results are fulfilled via its educational programming: (1) Knowledge and strategies for implementation of critical new developments in cancer treatment are brought forth to community oncology care teams; (2) The translational gap between discovery and delivery of care to the patient is bridged by providing content that is evidence-based and falls within the discipline of clinical medicine; (3) Continuing medical education activities are relevant and impact the professional practice of physicians, nurses, pharmacists and other members of healthcare teams who not only treat patients with cancer but others with weakened immune systems; (4) Activities impact the performance of physicians and other int 7 7 3 0 0 0 1300676 339309 0 0 2636 127093 107500 600 1410812 467002 0 0 0 0 138873 150232 0 0 0 746414 572299 885287 722531 525525 -255529 1832539 1525997 134555 118825 1697984 1407172 X The Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization that promotes high-quality, equitable patient care and fosters the discovery and clinical translation of important new therapies that enhance the practice of global oncology as well as supports the prevention and treatment of infectious diseases that impact cancer patients and others with weakened immune systems, thus helping protect the vulnerable from life-threatening infections. STO bridges a translational gap between drug discovery and approved drug delivery with a portfolio of educational activities for physicians and other members of the healthcare team. STO's decades-long commitment to translational research and education includes fellowships in both cancer and infectious diseases. The latter has become a critical STO commitment during the COVID-19 pandemic from the global genesis to worldwide distribution of new vaccines and improved therapeutics. STO is committed to diversity, inclusivity, 0 0 133514 HARMONY/GLOBAL HARMONIZATION OF CANCER TRIALS IS A MULTI-YEAR STO GUIDED INITIATIVE TO ENHANCE AND SUPPORT THE DEVELOPMENT OF NOVEL STRATEGIES FOR IMPROVED CANCER TREATMENT AND PREVENTION. GLOBAL HARMONIZATION WOULD ALLOW FOR SEAMLESS DEVELOPMENT OF CANCER THERAPIES USING COMMON STANDARDS AND BEST PRACTICES THAT HARMONIZE INDUSTRY, INSTITUTIONAL, AND REGULATORY PRACTICES ACROSS THE GLOBE. THE FOCUS OF THIS INITIATIVE IS TO ENCOURAGE HARMONIZATION ACROSS FOUR REGIONS: THE UNITED STATES, GOVERNED BY THE FEDERAL DRUG ADMINISTRATION (FDA); THE EUROPEAN UNION, GOVERNED BY THE EUROPEAN MEDICINES AGENCY (EMA); CHINA, GOVERNED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA); AND AFRICA, GOVERNED BY THE AFRICAN MEDICINES AGENCY (AMA). 130728 WE CONTINUED OUR ANNUAL INTENSIVE FORUM, STOFF, THAT BRINGS TOGETHER 25 FELLOWS AND JUNIOR CANCER RESEARCHERS WITHIN 5 YEARS OF TRAINING COMPLETION FROM LEADING MEDICAL, SURGICAL, RADIATION, AND PEDIATRIC ONCOLOGY GROUPS AND SUBSPECIALTY FELLOWSHIPS TO EDUCATE THESE RISING STARS ON ISSUES AROUND AND BARRIERS TO SUCCESSFUL TRANSLATIONAL CANCER RESEARCH. THE BROAD-BASED CURRICULUM COVERED A RANGE OF TOPICS RELATED TO NEW DRUG DEVELOPMENT. IN ADDITION, IT ADDRESSED KEY ISSUES THAT EARLY-CAREER ONCOLOGISTS MAY FACE. ONE OF THE HIGHLIGHTS OF STOFF AND WHAT SETS IT APART FROM OTHER PROGRAMS IS THE FACULTY TO FELLOW RATIO OF 1:1.5. TRAINEES HAVE UNIQUE OPPORTUNITIES TO CONNECT WITH OTHER SCIENTISTS AND CLINICIANS REGARDING TRANSLATIONAL RESEARCH EFFORTS THAT BENEFIT FROM MULTIDISCPLINARY AND INTERPROFESSIONAL INVESTIGATION. 45576 WE CONTINUED A MULTI-YEAR PARTNERSHIP WITH MD ANDERSON AND AXDEV WHICH WILL CONCLUDE IN 2024. THIS EDUCATIONAL PROGRAM PERFORMANCE IMPROVEMENT DEMONSTRATION PROJECT: OPTIMIZING INTEGRATION OF MOLECULAR TESTING IN LUNG AND THYROID CANCERS IS AIMED AT PROVIDING A ROADMAP OF LESSONS LEARNED TO RAISE AWARENESS OF MOLECULAR TESTING. THE OBJECTIVES ARE TO IDENTIFY THE ELEMENTS OF BEST PRACTICES FROM THE DEMONSTRATION PROJECT WHICH COULD BE REPLICATED IN OTHER INSTITUTIONS AND DEVELOP A NATIONAL EDUCATION PROGRAM TO GUIDE DEPLOYMENT OF SIMILAR INTERVENTIONS TO IMPROVE AWARENESS, ACCESS, AND INTEGRATION OF MOLECULAR TESTING ACROSS THE US AND MEASURE THE IMPACT (TO HELP OTHER COMMUNITY ONCOLOGY SITES WITHIN THE MDACC NETWORK AS WELL AS OUTSIDE OF IT). 97652 The Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization that promotes high-quality, equitable patient care and fosters the discovery and clinical translation of important new therapies that enhance the practice of global oncology as well as supports the prevention and treatment of infectious diseases that impact cancer patients and others with weakened immune systems, thus helping protect the vulnerable from life-threatening infections. STO bridges a translational gap between drug discovery and approved drug delivery with a portfolio of educational activities for physicians and other members of the healthcare team. STO's decades-long commitment to translational research and education includes fellowships in both cancer and infectious diseases. The latter has become a critical STO commitment during the COVID-19 pandemic from the global genesis to worldwide distribution of new vaccines and improved therapeutics. STO is committed to diversity, inclusivity, and equity throughout our programs. 97652 407470 1 1 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 21 0 3 1 0 0 0 0 0 0 0 0 0 0 X 7 7 1 0 0 0 1 0 0 1 1 0 0 1 1 1 1 1 0 0 0 0 X The Organization 9196415323 PO Box 12412 Durham NC 27709 Ann Murphy PHD Executive Director 1.00 40.00 X X 0 125122 0 Martin J Murphy DMEDSC PHD FASCO Chairman 1.00 X X 0 0 0 Kenneth B Lee MBA Treasurer 1.00 X X 0 0 0 Sean Khozin MD MPH Director 1.00 X 0 0 0 Ke Liu MD PHD Director 1.00 X 0 0 0 Mace L Rothenberg MD FACP Director 1.00 X 0 0 0 Lillian L Siu MD FRCPC FASCO Director 1.00 X 0 0 0 0 125122 0 0 0 0 0 AlphaMed Consulting Inc 3765 Hill Circle Colorado Springs CO 80904 Consulting services. 216947 1 339309 339309 49568 49568 697967 620442 77525 77525 77525 Rebate Income 900099 600 600 600 467002 600 0 127093 X 139556 63199 76357 10676 710 9966 15722 15722 3948 3032 916 26048 26048 294247 164648 129599 8113 5872 2241 3217 461 2756 51987 22369 29618 138012 138012 3314 3314 407 407 6015 6015 Miscellaneous 8000 8000 Bank Service Charges 5467 5467 Software 4159 25 4134 Dues & Subscriptions 1380 41 1339 2263 1101 1162 722531 407470 315061 0 30368 46558 751065 228662 100000 107 2114 14078 7421 6606 1222 815 947770 1235777 1832539 1525997 58857 116785 27000 48698 2040 134555 118825 X 1697984 404881 1002291 1697984 1407172 1832539 1525997 -255529 -35283 0 X 0 0 0 X 370600 285000 1128967 1300676 339309 3424552 370600 285000 1128967 1300676 339309 3424552 3424552 420 145 5365 31309 91809 129048 3553600 0.96370 0.57290 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7421 6606 815 815 Trilogy 1235777 C 1235777 Payroll Liabilities 2040 2040 East Asia and the Pacific 1 Educational Programs Advances clinical trial workshops, fellowships 37837 0 1 0 0 0 1 37837 0 37837 0 0 0 0 0 0 Form 990, Part VI, Section A, line 2 Martin and Ann Murphy are husband and wife and both serve as Directors on the Board. Form 990, Part VI, Section A, line 6 The Society is comprised of Members. The primary qualification for membership is to be an Oncologist or otherwise professionally involved with oncology. Form 990, Part VI, Section B, line 11b The completed Form 990 is reviewed by the Chairman and Treasurer of the Board of Directors. After this review, proposed changes are discussed with our tax accountant. If no changes are necessary, copies of the 990 are shared with the full Board and voted upon prior to filing. Form 990, Part VI, Section B, line 12c Conflict of interest disclosures are reviewed annually in accordance with the conflict of interest policy. Form 990, Part VI, Section C, line 19 The Society currently makes its Form 990, organizational documents, and conflict of interest policy available for public inspection upon request. Form 990, Part IX, line 11g International Support: Program service expenses 28,250. Management and general expenses 0. Fundraising expenses 0. Total expenses 28,250. Other Program Consultants: Program service expenses 30,069. Management and general expenses 0. Fundraising expenses 0. Total expenses 30,069. Staffing Contractors: Program service expenses 106,329. Management and general expenses 129,599. Fundraising expenses 0. Total expenses 235,928. AlphaMed Consulting Inc 3765 Hill Circle Colorado Springs CO 80904 311481027 Consulting CO S 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 AlphaMed Consulting Inc M 201897 AlphaMed Consulting Inc O 15050